These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

549 related articles for article (PubMed ID: 26153510)

  • 1. Protocol for Cerebral Microbleeds during the Non-Vitamin K Antagonist Oral Anticoagulants or Warfarin Therapy in Stroke Patients with Nonvalvular Atrial Fibrillation (CMB-NOW) Study: Multisite Pilot Trial.
    Takizawa S; Tanaka F; Nishiyama K; Hasegawa Y; Nagata E; Mizuma A; Yutani S; Nakayama T; Kobayashi H; Yanagimachi N; Okazaki T; Kitagawa K;
    J Stroke Cerebrovasc Dis; 2015 Sep; 24(9):2143-8. PubMed ID: 26153510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-vitamin k antagonist oral anticoagulants do not increase cerebral microbleeds.
    Saito T; Kawamura Y; Sato N; Kano K; Takahashi K; Asanome A; Sawada J; Katayama T; Hasebe N
    J Stroke Cerebrovasc Dis; 2015 Jun; 24(6):1373-7. PubMed ID: 25847305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study.
    Arihiro S; Todo K; Koga M; Furui E; Kinoshita N; Kimura K; Yamagami H; Terasaki T; Yoshimura S; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Nagakane Y; Kameda T; Hasegawa Y; Shibuya S; Ito Y; Nakashima T; Takamatsu K; Nishiyama K; Matsuki T; Homma K; Takasugi J; Tokunaga K; Sato S; Kario K; Kitazono T; Toyoda K;
    Int J Stroke; 2016 Jul; 11(5):565-74. PubMed ID: 26927811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of Recurrent Stroke Volume and Prognosis between Warfarin and Four Non-Vitamin K Antagonist Oral Anticoagulants' Administration for Secondary Prevention of Stroke.
    Kanai Y; Oguro H; Tahara N; Matsuda H; Takayoshi H; Mitaki S; Onoda K; Yamaguchi S
    J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):338-345. PubMed ID: 29033229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute management of stroke patients taking non-vitamin K antagonist oral anticoagulants Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) Registry: Design and rationale.
    Xian Y; Hernandez AF; Harding T; Fonarow GC; Bhatt DL; Suter RE; Khan Y; Schwamm LH; Peterson ED
    Am Heart J; 2016 Dec; 182():28-35. PubMed ID: 27914497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of non-vitamin K oral anticoagulant treatment compared with warfarin in patients with non-valvular atrial fibrillation who develop acute ischemic stroke or transient ischemic attack: a multicenter prospective cohort study (daVinci study).
    Saji N; Kimura K; Tateishi Y; Fujimoto S; Kaneko N; Urabe T; Tsujino A; Iguchi Y;
    J Thromb Thrombolysis; 2016 Nov; 42(4):453-62. PubMed ID: 27207691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New cerebral microbleeds in ischemic stroke patients on warfarin treatment: two-year follow-up.
    Orken DN; Uysal E; Timer E; Kuloglu-Pazarcı N; Mumcu S; Forta H
    Clin Neurol Neurosurg; 2013 Sep; 115(9):1682-5. PubMed ID: 23623660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends in oral anticoagulant choice for acute stroke patients with nonvalvular atrial fibrillation in Japan: the SAMURAI-NVAF study.
    Toyoda K; Arihiro S; Todo K; Yamagami H; Kimura K; Furui E; Terasaki T; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Kameda T; Nagakane Y; Hasegawa Y; Mochizuki H; Ito Y; Nakashima T; Takamatsu K; Nishiyama K; Kario K; Sato S; Koga M;
    Int J Stroke; 2015 Aug; 10(6):836-42. PubMed ID: 25581108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of oral anticoagulants in patients with atrial fibrillation.
    Greenspon AJ
    Postgrad Med; 2012 Nov; 124(6):7-16. PubMed ID: 23322134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative efficacy and safety of the non-vitamin K antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation.
    Senoo K; Lip GY
    Semin Thromb Hemost; 2015 Mar; 41(2):146-53. PubMed ID: 25682085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of non-vitamin K oral anticoagulants in non-valvular atrial fibrillation: a Bayesian meta-analysis approach.
    Verdecchia P; Angeli F; Bartolini C; De Filippo V; Aita A; Di Giacomo L; Poltronieri C; Lip GY; Reboldi G
    Expert Opin Drug Saf; 2015 Jan; 14(1):7-20. PubMed ID: 25311731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early administration of non-vitamin K antagonist oral anticoagulants for acute ischemic stroke patients with atrial fibrillation in comparison with warfarin mostly combined with heparin.
    Nomura E; Ohshita T; Imamura E; Wakabayashi S; Kajikawa H; Hosomi N; Matsumoto M
    Circ J; 2015; 79(4):862-6. PubMed ID: 25736910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors driving the use of warfarin and non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.
    Hu MM; Wang J; Chien KL; Su CL; Lin SY; Wu FL; Lin ZF
    J Formos Med Assoc; 2017 Apr; 116(4):276-286. PubMed ID: 27424804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
    Lip GY; Kongnakorn T; Phatak H; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Dorian P
    Clin Ther; 2014 Feb; 36(2):192-210.e20. PubMed ID: 24508420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prescription patterns of oral anticoagulants for patients with non-valvular atrial fibrillation: experience at a Japanese single institution.
    Tagaya M; Yoshikawa D; Sugishita Y; Yamauchi F; Ito T; Kamada T; Yoshinaga M; Mukaide D; Fujiwara W; Yokoi H; Hayashi M; Watanabe E; Ishii J; Ozaki Y; Izawa H
    Heart Vessels; 2016 Jun; 31(6):957-62. PubMed ID: 26022376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebral Microbleeds Do Not Predict Hemorrhagic Transformation in Acute Ischemic Stroke Patients with Atrial Fibrillation and/or Rheumatic Heart Disease.
    Liu J; Wang D; Li J; Lin J; Xiong Y; Liu B; Wei C; Wu B; Ma Z; Zhang S; Liu M
    Curr Neurovasc Res; 2017; 14(2):104-109. PubMed ID: 28294063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practical considerations in the use of novel oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation.
    Deitelzweig S
    Cardiovasc Ther; 2014 Apr; 32(2):74-81. PubMed ID: 24119252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials.
    Renda G; di Nicola M; De Caterina R
    Am J Med; 2015 Sep; 128(9):1007-14.e2. PubMed ID: 25910790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brain microbleeds, anticoagulation, and hemorrhage risk: Meta-analysis in stroke patients with AF.
    Charidimou A; Karayiannis C; Song TJ; Orken DN; Thijs V; Lemmens R; Kim J; Goh SM; Phan TG; Soufan C; Chandra RV; Slater LA; Haji S; Mok V; Horstmann S; Leung KT; Kawamura Y; Sato N; Hasebe N; Saito T; Wong LKS; Soo Y; Veltkamp R; Flemming KD; Imaizumi T; Srikanth V; Heo JH;
    Neurology; 2017 Dec; 89(23):2317-2326. PubMed ID: 29117953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.